Alembic Pharma Q1 net profit jumps over two-folds to Rs 301.46 crore

Drug firm Alembic Pharmaceuticals reported more than two-fold jump in net profit to Rs 301.46 crore for the quarter ended on June 30, 2020, mainly on account of robust sales in international markets

Alembic Pharmaceuticals ups its US game plan, acquires Orit
Alembic Pharmaceuticals
Press Trust of India New Delhi
1 min read Last Updated : Jul 22 2020 | 3:28 PM IST

Drug firm Alembic Pharmaceuticals on Wednesday reported more than two-fold jump in consolidated net profit to Rs 301.46 crore for the quarter ended on June 30, 2020, mainly on account of robust sales in international markets.

The company had posted a net profit of Rs 123.72 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals said in a filing to BSE.

Consolidated revenue from operations of the company stood at Rs 1,341.32 crore for the period under consideration against Rs 948.91 crore for the same period year ago, it added.

"It was an excellent quarter for the company backed by growth in all the international markets. Despite exceptionally, challenging circumstances, the operating teams ensured profitability and growth," Alembic Pharmaceuticals MD Pranav Amin said.

International formulations revenue grew 70 per cent to Rs 771 crore in the quarter, the company said.

Shares of Alembic Pharmaceuticals were trading at Rs 1,010.15 on BSE, up 1.55 per cent from the previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Alembic PharmaQ2 results

First Published: Jul 22 2020 | 3:19 PM IST

Next Story